November 17, 2016

Novocure Presents Interim STELLAR Results at IASLC Suggesting Treatment with Tumor Treating Fields Plus Chemotherapy may Extend Survival of Patients with Mesothelioma

One-year survival rates of patients treated with Tumor Treating Fields combined with pemetrexed and cisplatin or carboplatin were more than 58% greater than historical control data One-year survival rates of patients treated with Tumor Treating Fields combined with pemetrexed and cisplatin or carboplatin were more than 58%… Read More
learn more
November 14, 2016

Novocure Sponsors Pulitzer Prize-Winning Author Dr. Siddhartha Mukherjee as Keynote Speaker of 21st Annual Scientific Meeting of the Society for Neuro-Oncology

Dr. Mukherjee wrote Pulitzer Prize-Winning book The Emperor of All Maladies and New York Times bestseller The Gene. Dr. Mukherjee wrote Pulitzer Prize-Winning book The Emperor of All Maladies and New York Times bestseller The Gene. Novocure has sponsored Pulitzer Prize-winning… Read More
learn more
November 14, 2016

Novocure Sponsors Pulitzer Prize-Winning Author Dr. Siddhartha Mukherjee as Keynote Speaker of 21st Annual Scientific Meeting of the Society for Neuro-Oncology

Dr. Mukherjee wrote Pulitzer Prize-Winning book The Emperor of All Maladies and New York Times bestseller The Gene. Dr. Mukherjee wrote Pulitzer Prize-Winning book The Emperor of All Maladies and New York Times bestseller The Gene. Novocure has sponsored Pulitzer Prize-winning… Read More
learn more
November 14, 2016

Novocure Sponsors Pulitzer Prize-Winning Author Dr. Siddhartha Mukherjee as Keynote Speaker of 21st Annual Scientific Meeting of the Society for Neuro-Oncology

Dr. Mukherjee wrote Pulitzer Prize-Winning book The Emperor of All Maladies and New York Times bestseller The Gene. Dr. Mukherjee wrote Pulitzer Prize-Winning book The Emperor of All Maladies and New York Times bestseller The Gene. Novocure has sponsored Pulitzer Prize-winning… Read More
learn more
November 7, 2016

Novocure Announces 38 Presentations on Tumor Treating Fields at 21st Annual Scientific Meeting of the Society of Neuro-Oncology

28 of 38 abstracts were prepared by external researchers, representing increasing interest in Novocure’s proprietary therapy 28 of 38 abstracts were prepared by external researchers, representing increasing interest in Novocure’s proprietary therapy The long-term analysis of all 695 patients enrolled in its phase 3… Read More
learn more
November 7, 2016

Novocure Announces 38 Presentations on Tumor Treating Fields at 21st Annual Scientific Meeting of the Society of Neuro-Oncology

28 of 38 abstracts were prepared by external researchers, representing increasing interest in Novocure’s proprietary therapy 28 of 38 abstracts were prepared by external researchers, representing increasing interest in Novocure’s proprietary therapy The long-term analysis of all 695 patients enrolled in its phase 3… Read More
learn more
November 7, 2016

Novocure Announces 38 Presentations on Tumor Treating Fields at 21st Annual Scientific Meeting of the Society of Neuro-Oncology

28 of 38 abstracts were prepared by external researchers, representing increasing interest in Novocure’s proprietary therapy 28 of 38 abstracts were prepared by external researchers, representing increasing interest in Novocure’s proprietary therapy The long-term analysis of all 695 patients enrolled in its phase 3… Read More
learn more
November 3, 2016

United Healthcare Issues Positive Coverage Decision for Optune

As of Jan. 1, 2017, more than 177 million Americans will have coverage of Optune as a treatment for newly diagnosed and/or recurrent glioblastoma As of Jan. 1, 2017, more than 177 million Americans will have coverage of Optune as a treatment for newly diagnosed and/or recurrent… Read More
learn more
November 3, 2016

United Healthcare Issues Positive Coverage Decision for Optune

As of Jan. 1, 2017, more than 177 million Americans will have coverage of Optune as a treatment for newly diagnosed and/or recurrent glioblastoma As of Jan. 1, 2017, more than 177 million Americans will have coverage of Optune as a treatment for newly diagnosed and/or recurrent… Read More
learn more
November 3, 2016

United Healthcare Issues Positive Coverage Decision for Optune

As of Jan. 1, 2017, more than 177 million Americans will have coverage of Optune as a treatment for newly diagnosed and/or recurrent glioblastoma As of Jan. 1, 2017, more than 177 million Americans will have coverage of Optune as a treatment for newly diagnosed and/or recurrent… Read More
learn more